SESSION TITLE: COPD Pharmacotherapy
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM
PURPOSE: To evaluate the effectiveness of the aclidinium bromide (322 mcg twice a day) in improving nocturnal oxygen saturation in COPD patients (B-C stages).
METHODS: We examined 100 patients, all affected by the same COPD severity according to GOLD guidelines (B-C stages). All patients, at the enrolment, filled in a questionnaire on the presence of the following symptoms: a) excessive daytime sleepiness; b) choking or gaspingduring sleep; c) recurrent awakenings from sleep; d) unrefreshing sleep; e) daytime fatigue; f) morning headaches; g) nicturia. We studied the nocturnal oxygen saturation of patients who presented symptoms. 45 patients had sleep disordered breathing with desaturation. All 45 patients were treated aclidinium bromide (322 mcg twice a day). Patients were re-evaluated after 15 days of treatment.